en Experimental research article Experimental research article <span style="FONT-SIZE: 12pt FONT-FAMILY: "Palatino Linotype" mso-fareast-font-family: 'Times New Roman' mso-bidi-font-family: 'Times New Roman' mso-ansi-language: EN-US mso-fareast-language: EN-US mso-bidi-language: AR-SA">In this study the effect of adrenergic receptor agonists and antagonists on physostigmine induced yawning was investigated. Intraperitoneal injection of different doses of physostigmine (0.03, 0.05, 0.1 and 0.2 mg/kg) caused yawning in white rats. The greatest response was seen at a dose of 0.2 mg/kg physostigmine. Phenylephrine, an α₁ agonist, and clonidine, an α₂ agonist, led to a decrease in physostigmine-induced yawning. Prazosine and high-dose phenoxybenzamine decreased the inhibitory effect of phenylephrine. Also, high doses of yohimbine decreased the effect of clonidine. Adrenergic receptor antagonists phenoxybenzamine, prazosine and propranolol had no significant effect on the physostigmine-induced response, while the α₂ antagonist (yohimbine) and low-dose prazosine decreased physostigmine's effect. Based on these results, we may conclude that activation of α₁ and α₂ receptors leads to a decrease in physostigmine-induced yawning in rats.</span> Adrenergic system; Dopaminergic system; Cholinergic system; Physostigmine; Yawning 105 110 http://ppj.phypha.ir/browse.php?a_code=A-10-110-63&slc_lang=en&sid=1